Meissner M D, Nestico P F, Morganroth J
Clin Ther. 1986;8(6):595-604.
Ventricular tachyarrhythmia is the most common terminal event causing sudden cardiac death. Risk stratification using 24-hour Holter monitoring to identify ventricular ectopy and noninvasive techniques to detect abnormal left ventricular function is becoming routine. Many cardiologists treat patients with potentially lethal ventricular arrhythmias even though it is unknown as yet whether sudden cardiac death can be prevented. Patients with lethal ventricular arrhythmias are always treated. A number of new oral antiarrhythmic agents have become available to the clinician. The modified Vaughan-Williams classification system categorizes the drugs according to their electrophysiologic and clinical characteristics. The class IC antiarrhythmic agents are emerging as the potential drugs of first choice for patients with benign or potentially lethal ventricular arrhythmias. The betablockers (class II) are used as antiarrhythmic agents, particularly in the presence of active myocardial ischemia or high catecholamine levels and in the postmyocardial infarction patient. Amiodarone (class III) may cause serious side effects and is reserved for patients with lethal ventricular arrhythmias when all other available agents have failed.
室性快速心律失常是导致心源性猝死最常见的终末事件。利用24小时动态心电图监测进行风险分层以识别室性早搏，以及采用无创技术检测左心室功能异常正成为常规操作。许多心脏病专家会治疗患有潜在致命性室性心律失常的患者，尽管目前尚不清楚心源性猝死是否能够预防。患有致命性室性心律失常的患者总会接受治疗。临床医生已有多种新型口服抗心律失常药物可供使用。改良的 Vaughan-Williams 分类系统根据药物的电生理和临床特征对其进行分类。IC类抗心律失常药物正成为治疗良性或潜在致命性室性心律失常患者的潜在首选药物。β受体阻滞剂（II类）用作抗心律失常药物，尤其适用于存在活动性心肌缺血或高儿茶酚胺水平的情况以及心肌梗死后患者。胺碘酮（III类）可能会引起严重副作用，仅在所有其他可用药物均无效时用于治疗致命性室性心律失常患者。
